Drug Profile
Research programme: stem cell therapy - Cellaion
Latest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Cytonet
- Class
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver disorders; Liver failure
Most Recent Events
- 05 Oct 2017 Promethera Biosciences and Shibuya enter into collaboration to develop manufacturing platform for stem cell therapies for treatment of liver disorders
- 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-disorders in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-failure in Germany